{"ticker": {"uuid": "24f71033-d2ba-427b-9da6-733808a99146", "symbol": "HCM", "name": "HUTCHMED  DRC", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "HUTCHMED (China) Ltd (HCM) Shares Surge 3.0% -- What GF Score of 79 Tells Investors", "summary": "HUTCHMED (China) Ltd (HCM) shares surged 3.0% to $11.60 on July 15, 2026. The company is considered modestly undervalued with a GF Value\u2122 of $13.72, and its GF Score\u2122 of 79/100 indicates above-average performance with strong growth and valuation, despite lower profitability. No i", "url": "https://www.gurufocus.com/news/8961408/hutchmed-china-ltd-hcm-shares-surge-30-what-gf-score-of-79-tells-investors?mobile=true", "source_name": "GuruFocus", "published_at": "2026-07-16T00:10:10", "published_display": "16 Jul 2026 00:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HCM Acquisition Corp (NASDAQ:HCMA) Sees Significant Decrease in Short Interest", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxON3FUWkNTdGRQb1JYMzNrWUNDcHR1ZWMzODFJTDk1aDRLQ2ZlZ1pkSVNTaXpNc1BYWW9PdHh0cXdSeXhlTVFjXzZUb09IYWlJZV91ZzNEd2xRZ0RFUDZWNXVGck9jM0Q2WTVTYl9RdTdWSnJVcmluYzV3VDEza05tTlN5RTNqLWF5d1lyemlMM1BmRlJxUXp3RERoMkRVSzExQUNnd0FvV0RnVW5RTGhVWEFXV25IN2JsakwtSjh6NTdwYmhqMUpPXw?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-13T00:07:15+00:00", "published_display": "13 Jul 2026 00:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Have Conflicting Sentiments on These Healthcare Companies: HUTCHMED (HCM), Axsome Therapeutics (AXSM) and Vertex Pharmaceuticals (VRTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwJBVV95cUxQcld6djEzWkZneEJVSURYT0tHbmF2MkFhS19kZG9MbVNySFJyUDBuV1RtV2JQQkprQjdxc3lrOXU3OE8xbTNJSXRJU3hTS3NMeE5RWkE0TzVpSEhpZjJKM01FU25SZEVRMmdCRXlkT19CaXlBVWYzM1hSdGpHYzdSclZJT2xuTjRUNElMUDN6YVc2QTR4d1dpa2N3SFdHMldGTHpLSVRzVktjai1YekdJa0hzV3AxenNaZG9SRk9fVzctRGIxUWhUMjZyb00xbGkxckNtaE51ai1aYllQUmdWc3JBQ3ppbU1tTnY1dmw5WEJwRlE3bzc3UXNxeVlHVG5qc185Zll3ZGowcHpaWlU3QmRsak42dVJJQ2hsaUl2QlpQbmFVLW1xRUwwMmpsdGpyc2JTVjRuSEpBVGlEYkQ1enZQUQ?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-08T10:42:00+00:00", "published_display": "08 Jul 2026 10:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA Securities Maintains Hutchmed (China)(HCM.US) With Buy Rating, Cuts Target Price to $17", "summary": "BofA Securities has reiterated its Buy rating for Hutchmed (China) (HCM.US) but has adjusted its target price downwards to $17. This indicates continued confidence in the company's prospects despite a revised valuation.", "url": "https://www.moomoo.com/news/post/72580537/bofa-securities-maintains-hutchmed-china-hcmus-with-buy-rating-cuts", "source_name": "Moomoo", "published_at": "2026-07-08T04:10:38", "published_display": "08 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUTCHMED Announces NMPA Approval for ORPATHYS\u00ae for the treatment of Gastric Cancer Patients with MET Amplification", "summary": "HUTCHMED (China) Limited announced that its drug ORPATHYS\u00ae (savolitinib) received conditional approval from China's National Medical Products Administration (NMPA) for treating advanced gastric cancer or gastroesophageal junction adenocarcinoma patients with MET amplification who", "url": "https://finance.yahoo.com/healthcare/articles/hutchmed-announces-nmpa-approval-orpathys-083000461.html", "source_name": "Market source", "published_at": "2026-07-03T04:10:38", "published_display": "03 Jul 2026 04:10", "sentiment": "positive", "sentiment_pct": 88, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUTCHMED stock surges on China gastric cancer drug approval By Investing.com", "summary": "HUTCHMED shares surged by 6.5% following the conditional approval of its drug ORPATHYS\u00ae (savolitinib) in China for advanced gastric cancer or gastroesophageal junction adenocarcinoma. This marks the first selective MET inhibitor approved for this patient population in China, targ", "url": "https://ca.investing.com/news/stock-market-news/hutchmed-stock-surges-on-china-gastric-cancer-drug-approval-93CH-4718554", "source_name": "Investing.com Canada", "published_at": "2026-07-03T03:09:50", "published_display": "03 Jul 2026 03:09", "sentiment": "positive", "sentiment_pct": 94, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hutchmed drug approved in China for advanced gastric cancer", "summary": "Hutchmed China Ltd has received conditional approval from China's NMPA for its drug savolitinib ('ORPATHYS') to treat advanced gastric cancer patients with MET amplification, a condition with poor prognosis. This marks the drug's third approved indication in China and is a joint ", "url": "https://www.lse.co.uk/news/hutchmed-drug-approved-in-china-for-advanced-gastric-cancer-pzlgag46dmqwhbo.html", "source_name": "London South East", "published_at": "2026-07-02T13:25:39", "published_display": "02 Jul 2026 13:25", "sentiment": "positive", "sentiment_pct": 91, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUTCHMED wins China approval for ORPATHYS cancer drug", "summary": "HUTCHMED (NASDAQ:HCM) has received conditional approval from China's National Medical Products Administration for its cancer drug ORPATHYS (savolitinib). This approval is for the treatment of MET-amplified advanced gastric or gastroesophageal junction adenocarcinoma in patients w", "url": "https://grafa.com/en/news/united-states/hutchmed-orpathys-nmpa-approval-gastric-cancer", "source_name": "grafa.com", "published_at": "2026-07-02T12:40:41", "published_display": "02 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AIM movers: Hutchmed granted new drug application in China and ex-dividends", "summary": "Hutchmed (China) Ltd saw its share price jump after receiving conditional approval for its new drug ORPATHYS in China. Other companies like James Cropper, Zephyr Energy, James Latham, Sintana Energy, and Huddled Group also experienced share price increases due to positive develop", "url": "https://ukinvestormagazine.co.uk/aim-movers-hutchmed-granted-new-drug-application-in-china-and-ex-dividends/", "source_name": "UK Investor Magazine", "published_at": "2026-07-02T10:40:39", "published_display": "02 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NMPA clears HUTCHMED (HCM) drug ORPATHYS for MET-amplified gastric cancer", "summary": "HUTCHMED (HCM) has received conditional approval from China's National Medical Products Administration (NMPA) for its drug ORPATHYS (savolitinib) to treat locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with MET amplification, after at least two", "url": "https://www.stocktitan.net/sec-filings/HCM/6-k-hutchmed-china-ltd-current-report-foreign-issuer-03280d44d1ba.html", "source_name": "Stock Titan", "published_at": "2026-07-02T09:40:39", "published_display": "02 Jul 2026 09:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REG - Hutchmed China Ltd - HUTCHMED Announces NMPA Approval for ORPATHYS", "summary": "HUTCHMED (China) Limited announced that the China National Medical Products Administration (NMPA) has granted conditional approval for ORPATHYS\u00ae (savolitinib) to treat locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with MET ampl", "url": "https://www.tradingview.com/news/reuters.com,2026-07-02:newsml_RSB7781Ka:0-reg-hutchmed-china-ltd-hutchmed-announces-nmpa-approval-for-orpathys/", "source_name": "TradingView", "published_at": "2026-07-02T08:40:39", "published_display": "02 Jul 2026 08:40", "sentiment": "positive", "sentiment_pct": 93, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUTCHMED receives China approval for ORPATHYS in gastric cancer By Investing.com", "summary": "HUTCHMED announced that China's National Medical Products Administration has granted conditional approval for ORPATHYS (savolitinib) to treat advanced gastric cancer or gastroesophageal junction adenocarcinoma with MET amplification. This marks the first selective MET inhibitor a", "url": "https://ca.investing.com/news/stock-market-news/hutchmed-receives-china-approval-for-orpathys-in-gastric-cancer-93CH-4717673", "source_name": "Investing.com Canada", "published_at": "2026-07-02T08:40:39", "published_display": "02 Jul 2026 08:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "China approves HUTCHMED\u2019s ORPATHYS for MET-driven gastric cancer", "summary": "HUTCHMED (HCM) has received conditional NMPA approval in China for ORPATHYS (savolitinib) to treat locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with MET amplification. This approval marks the third indication for ORPATHYS in China and ", "url": "https://www.stocktitan.net/news/HCM/hutchmed-announces-nmpa-approval-for-orpathys-for-the-treatment-of-jcjoi1jarp14.html", "source_name": "Stock Titan", "published_at": "2026-07-02T08:40:39", "published_display": "02 Jul 2026 08:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUTCHMED to Announce 2026 Half-Year Financial Results", "summary": "HUTCHMED (China) Limited will announce its interim results for the first half of 2026 on Thursday, July 30, 2026. The company will host two webcast presentations for analysts and investors, one in English and one in Chinese (Putonghua), following the results announcement. These w", "url": "https://finance.yahoo.com/healthcare/articles/hutchmed-announce-2026-half-financial-083000053.html", "source_name": "Market source", "published_at": "2026-07-01T02:10:13", "published_display": "01 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUTCHMED to announce 2026 interim results on July 30", "summary": "HUTCHMED (China) Limited will release its interim financial results for the first half of 2026 on July 30, 2026. The company, focused on biopharmaceutical development for cancer and immunological diseases, will host two webcasts\u2014one in English and one in Chinese\u2014to discuss the re", "url": "https://scanx.trade/stock-market-news/companies/hutchmed-to-announce-2026-interim-results-on-july-30/44354258", "source_name": "scanx.trade", "published_at": "2026-06-30T11:40:54", "published_display": "30 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUTCHMED (NASDAQ: HCM) schedules 2026 half-year results and investor webcasts", "summary": "HUTCHMED (NASDAQ: HCM) has announced it will release its interim results for the first half of 2026 on Thursday, July 30, 2026. Management will host two webcasts for investors and analysts: an English webcast on July 30 and a Putonghua webcast on July 31. The company is a commerc", "url": "https://www.stocktitan.net/sec-filings/HCM/6-k-hutchmed-china-ltd-current-report-foreign-issuer-d3a5fb04297a.html", "source_name": "Stock Titan", "published_at": "2026-06-30T09:40:21", "published_display": "30 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUTCHMED to post half-year results July 30, with analyst webcasts", "summary": "HUTCHMED (Nasdaq/AIM: HCM; HKEX:13) announced it will release its 2026 half-year financial results on Thursday, July 30, 2026, at 7:00 am EDT. The company will host English and Chinese webcasts with Q&A sessions for analysts and investors, accessible live and via replay on its we", "url": "https://www.stocktitan.net/news/HCM/hutchmed-to-announce-2026-half-year-financial-7z0e5vutd92w.html", "source_name": "Stock Titan", "published_at": "2026-06-30T08:40:21", "published_display": "30 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REG - Hutchmed China Ltd - HUTCHMED to Announce 2026 Half-Year Results", "summary": "HUTCHMED (China) Limited will announce its interim financial results for the six months ended June 30, 2026, on Thursday, July 30, 2026. The company will host two webcast presentations for analysts and investors to discuss these results, with an English webcast on July 30 and a C", "url": "https://www.tradingview.com/news/reuters.com,2026-06-30:newsml_RSd2351Ka:0-reg-hutchmed-china-ltd-hutchmed-to-announce-2026-half-year-results/", "source_name": "TradingView", "published_at": "2026-06-30T08:40:20", "published_display": "30 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUTCHMED (HCM) details 2015 and 2026 share option blocklisting return", "summary": "HUTCHMED (China) Limited has filed a blocklisting six-monthly return for its 2015 and 2026 Share Option Schemes, covering the period from December 29, 2025, to June 28, 2026. The report details the issuance of 7,500 ordinary shares under the 2015 scheme, with 45,768,368 shares re", "url": "https://www.stocktitan.net/sec-filings/HCM/6-k-hutchmed-china-ltd-current-report-foreign-issuer-a51ed28dfa4e.html", "source_name": "Stock Titan", "published_at": "2026-06-29T10:39:27", "published_display": "29 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REG - Hutchmed China Ltd - Announcement on blocklisting six monthly return", "summary": "HUTCHMED (China) Limited has published its blocklisting six-monthly return for the period from December 29, 2025, to June 28, 2026. The report details the activity for two share option schemes, including the number of shares balance, increases, and securities issued during the pe", "url": "https://www.tradingview.com/news/reuters.com,2026-06-29:newsml_RSc0272Ka:0-reg-hutchmed-china-ltd-announcement-on-blocklisting-six-monthly-return/", "source_name": "TradingView", "published_at": "2026-06-29T08:39:27", "published_display": "29 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pivotal Phase II Results Advance HUTCHMED\u2019s Fanregratinib Towards China Approval In ICC", "summary": "HUTCHMED's fanregratinib has shown pivotal Phase II results, moving it closer to approval in China for intrahepatic cholangiocarcinoma (ICC). The article highlights the company's progress and mentions related news concerning competitors and other approvals in the field of cholang", "url": "https://insights.citeline.com/scrip/r-and-d/clinical-trials/pivotal-phase-ii-results-advance-hutchmeds-fanregratinib-towards-china-approval-in-icc-MSXLOHEOINE5XLW6DVRRCE5J5I/", "source_name": "Citeline News & Insights", "published_at": "2026-06-26T09:46:45", "published_display": "26 Jun 2026 09:46", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hutchmed Says Phase 2 Trial for Investigational Cancer Drug Meets Primary Endpoint", "summary": "Hutchmed announced that its investigational cancer drug, sovleplenib, met its primary endpoint in a Phase 2 trial. The study focused on adult patients with primary immune thrombocytopenia (ITP) who had previously failed at least one prior therapy. This positive outcome marks a si", "url": "https://www.moomoo.com/news/post/72026554/hutchmed-says-phase-2-trial-for-investigational-cancer-drug-meets?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-25T22:39:56", "published_display": "25 Jun 2026 22:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUTCHMED quarterly timing, shares steady on Nasdaq", "summary": "HUTCHMED (China) Ltd, an oncology-focused biotech company, is preparing to release its interim 2026 financial results in late August. While analysts hold mixed views on the stock, it trades steadily on Nasdaq, with its valuation sensitive to trial news and regulatory decisions. T", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/hutchmed-quarterly-timing-shares-steady-on-nasdaq/69627758", "source_name": "Ad-hoc-news.de", "published_at": "2026-06-25T20:11:50", "published_display": "25 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUTCHMED reports 42.5% fanregratinib response rate", "summary": "HUTCHMED announced positive Phase II data for its drug fanregratinib in patients with advanced intrahepatic cholangiocarcinoma, showing a 42.5% objective response rate in a single-arm trial conducted in China. The data supports a New Drug Application that has received priority re", "url": "https://grafa.com/en/news/united-states/hutchmed-fanregratinib-phase-ii-42-response-rate", "source_name": "grafa.com", "published_at": "2026-06-25T15:18:00", "published_display": "25 Jun 2026 15:18", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026", "summary": "HUTCHMED has released pivotal Phase II data for its drug fanregratinib (HMPL-453) in patients with intrahepatic cholangiocarcinoma (ICC) harboring FGFR2-fusions/rearrangements, which will be presented at the ESMO Gastrointestinal Cancers Congress 2026. The registration-enabling s", "url": "https://www.manilatimes.net/2026/06/25/tmt-newswire/globenewswire/hutchmed-highlights-pivotal-phase-ii-data-for-fanregratinib-in-intrahepatic-cholangiocarcinoma-presented-at-esmo-gastrointestinalcancers-congress-2026/2372436", "source_name": "The Manila Times", "published_at": "2026-06-25T12:40:21", "published_display": "25 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hutchmed China reports positive phase two fanregratinib study data", "summary": "Hutchmed China Ltd has reported positive phase two data for its drug fanregratinib, used to treat intrahepatic cholangiocarcinoma (ICC) in patients with fibroblast growth factor receptor two fusion/rearrangement. The study, conducted across 53 sites in China, met its primary endp", "url": "https://www.lse.co.uk/news/hutchmed-china-reports-positive-phase-two-fanregratinib-study-data-1yf3o07srvxfmvp.html", "source_name": "London South East", "published_at": "2026-06-25T11:25:00", "published_display": "25 Jun 2026 11:25", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pivotal fanregratinib ICC data and China NDA review for HUTCHMED (NASDAQ: HCM)", "summary": "HUTCHMED (NASDAQ: HCM) has reported pivotal Phase II data for its FGFR inhibitor fanregratinib in patients with advanced intrahepatic cholangiocarcinoma (ICC) harboring FGFR2 fusions or rearrangements. The study met its primary endpoint with an objective response rate of 42.5% an", "url": "https://www.stocktitan.net/sec-filings/HCM/6-k-hutchmed-china-ltd-current-report-foreign-issuer-bb54ad3c6970.html", "source_name": "Stock Titan", "published_at": "2026-06-25T10:11:49", "published_display": "25 Jun 2026 10:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RCS - Hutchmed China Ltd - HUTCHMED Highlights Phase II Data at ESMO", "summary": "HUTCHMED announced positive pivotal Phase II data for fanregratinib in intrahepatic cholangiocarcinoma (ICC) patients with FGFR2-fusions/rearrangements, to be presented at the ESMO Gastrointestinal Cancers Congress 2026. The study demonstrated a 42.5% objective response rate and ", "url": "https://www.tradingview.com/news/reuters.com,2026-06-25:newsml_RSY6204Ja:0-rcs-hutchmed-china-ltd-hutchmed-highlights-phase-ii-data-at-esmo/", "source_name": "TradingView", "published_at": "2026-06-25T06:11:49", "published_display": "25 Jun 2026 06:11", "sentiment": "positive", "sentiment_pct": 87, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUTCHMED analyst targets stay high, shares trade well below consensus", "summary": "HUTCHMED (HCM) shares are trading significantly below analyst price targets, with the ADR closing around $10 while the consensus target remains above $20. The average analyst price target for HUTCHMED ADR is $21.07, representing over 100% upside from its current price, and the co", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/hutchmed-analyst-targets-stay-high-shares-trade-well-below-consensus/69612949", "source_name": "AD HOC NEWS", "published_at": "2026-06-23T18:40:23", "published_display": "23 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 69, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/hutchmed-highlights-sovleplenib-eslim-02-000000864.html", "source_name": "GlobeNewswire", "published_at": "2026-06-12T00:00:00+00:00", "published_display": "12 Jun 2026 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why HUTCHMED (China) Limited (HCM) Is Gaining Attention After China Biotech Re-Rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQRFFZbzFnWWV2S09idXNwVVFqZ2c1Sl9sellQNHZGb2pEMVZlYnZDLS1ZQXlaTGNwRlpzN00wUm5EUUhjVzdrTC1yVGwtWVlucUZZeXNpdFNSYndrUHoxY0xESEkxZS1TMXpfVWcteTFDX3JBbnB4S2MtSnBGLWFhaUt3M3hpMk1YbjJjRG1iWW1OV2JGcVBEQ3ptNDB6NXAx?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hutchmed stock hits 52-week low at 11.7 USD", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQaFJHUWxSLXVjY1dlbjRXdjJ6Mi1WZzBFdHZ3aWZXV2J4TEQ2ZFA2ejdoRi03bjlkdXhzVC0wMURtWmNJTHBrMXNjZHhqZG1TU29HYkllYmcydGlsYmprWUk1cFJXS3dYQ3hDRkQ0dDJ6UDYtaW5kUkNCaE5OdGhqdldKVjJ1MUdZdk0zTFZrNlRzSE1yd0ZCT0oxOUMzWjA?oc=5", "source_name": "Investing.com", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT\u00ae (Sintilimab Injection) in Combination with ELUNATE\u00ae (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/innovent-hutchmed-jointly-announce-nmpa-100000286.html", "source_name": "PR Newswire", "published_at": "2026-05-21T10:00:00+00:00", "published_display": "21 May 2026 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE\u00ae (Fruquintinib) in Combination with TYVYT\u00ae (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/hutchmed-innovent-jointly-announce-nmpa-100000086.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T10:00:00+00:00", "published_display": "21 May 2026 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/hutchmed-announces-nda-acceptance-china-100000447.html", "source_name": "GlobeNewswire", "published_at": "2026-04-29T10:00:00+00:00", "published_display": "29 Apr 2026 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "HUTCHMED (China) Ltd (HCM) Shares Surge 3.0% -- What GF Score of 79 Tells Investors", "summary": "HUTCHMED (China) Ltd (HCM) shares surged 3.0% to $11.60 on July 15, 2026. The company is considered modestly undervalued with a GF Value\u2122 of $13.72, and its GF Score\u2122 of 79/100 indicates above-average performance with strong growth and valuation, despite lower profitability. No i", "url": "https://www.gurufocus.com/news/8961408/hutchmed-china-ltd-hcm-shares-surge-30-what-gf-score-of-79-tells-investors?mobile=true", "source_name": "GuruFocus", "published_at": "2026-07-16T00:10:10", "published_display": "16 Jul 2026 00:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HCM Acquisition Corp (NASDAQ:HCMA) Sees Significant Decrease in Short Interest", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxON3FUWkNTdGRQb1JYMzNrWUNDcHR1ZWMzODFJTDk1aDRLQ2ZlZ1pkSVNTaXpNc1BYWW9PdHh0cXdSeXhlTVFjXzZUb09IYWlJZV91ZzNEd2xRZ0RFUDZWNXVGck9jM0Q2WTVTYl9RdTdWSnJVcmluYzV3VDEza05tTlN5RTNqLWF5d1lyemlMM1BmRlJxUXp3RERoMkRVSzExQUNnd0FvV0RnVW5RTGhVWEFXV25IN2JsakwtSjh6NTdwYmhqMUpPXw?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-13T00:07:15+00:00", "published_display": "13 Jul 2026 00:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Have Conflicting Sentiments on These Healthcare Companies: HUTCHMED (HCM), Axsome Therapeutics (AXSM) and Vertex Pharmaceuticals (VRTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwJBVV95cUxQcld6djEzWkZneEJVSURYT0tHbmF2MkFhS19kZG9MbVNySFJyUDBuV1RtV2JQQkprQjdxc3lrOXU3OE8xbTNJSXRJU3hTS3NMeE5RWkE0TzVpSEhpZjJKM01FU25SZEVRMmdCRXlkT19CaXlBVWYzM1hSdGpHYzdSclZJT2xuTjRUNElMUDN6YVc2QTR4d1dpa2N3SFdHMldGTHpLSVRzVktjai1YekdJa0hzV3AxenNaZG9SRk9fVzctRGIxUWhUMjZyb00xbGkxckNtaE51ai1aYllQUmdWc3JBQ3ppbU1tTnY1dmw5WEJwRlE3bzc3UXNxeVlHVG5qc185Zll3ZGowcHpaWlU3QmRsak42dVJJQ2hsaUl2QlpQbmFVLW1xRUwwMmpsdGpyc2JTVjRuSEpBVGlEYkQ1enZQUQ?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-08T10:42:00+00:00", "published_display": "08 Jul 2026 10:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA Securities Maintains Hutchmed (China)(HCM.US) With Buy Rating, Cuts Target Price to $17", "summary": "BofA Securities has reiterated its Buy rating for Hutchmed (China) (HCM.US) but has adjusted its target price downwards to $17. This indicates continued confidence in the company's prospects despite a revised valuation.", "url": "https://www.moomoo.com/news/post/72580537/bofa-securities-maintains-hutchmed-china-hcmus-with-buy-rating-cuts", "source_name": "Moomoo", "published_at": "2026-07-08T04:10:38", "published_display": "08 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUTCHMED Announces NMPA Approval for ORPATHYS\u00ae for the treatment of Gastric Cancer Patients with MET Amplification", "summary": "HUTCHMED (China) Limited announced that its drug ORPATHYS\u00ae (savolitinib) received conditional approval from China's National Medical Products Administration (NMPA) for treating advanced gastric cancer or gastroesophageal junction adenocarcinoma patients with MET amplification who", "url": "https://finance.yahoo.com/healthcare/articles/hutchmed-announces-nmpa-approval-orpathys-083000461.html", "source_name": "Market source", "published_at": "2026-07-03T04:10:38", "published_display": "03 Jul 2026 04:10", "sentiment": "positive", "sentiment_pct": 88, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUTCHMED stock surges on China gastric cancer drug approval By Investing.com", "summary": "HUTCHMED shares surged by 6.5% following the conditional approval of its drug ORPATHYS\u00ae (savolitinib) in China for advanced gastric cancer or gastroesophageal junction adenocarcinoma. This marks the first selective MET inhibitor approved for this patient population in China, targ", "url": "https://ca.investing.com/news/stock-market-news/hutchmed-stock-surges-on-china-gastric-cancer-drug-approval-93CH-4718554", "source_name": "Investing.com Canada", "published_at": "2026-07-03T03:09:50", "published_display": "03 Jul 2026 03:09", "sentiment": "positive", "sentiment_pct": 94, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hutchmed drug approved in China for advanced gastric cancer", "summary": "Hutchmed China Ltd has received conditional approval from China's NMPA for its drug savolitinib ('ORPATHYS') to treat advanced gastric cancer patients with MET amplification, a condition with poor prognosis. This marks the drug's third approved indication in China and is a joint ", "url": "https://www.lse.co.uk/news/hutchmed-drug-approved-in-china-for-advanced-gastric-cancer-pzlgag46dmqwhbo.html", "source_name": "London South East", "published_at": "2026-07-02T13:25:39", "published_display": "02 Jul 2026 13:25", "sentiment": "positive", "sentiment_pct": 91, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUTCHMED wins China approval for ORPATHYS cancer drug", "summary": "HUTCHMED (NASDAQ:HCM) has received conditional approval from China's National Medical Products Administration for its cancer drug ORPATHYS (savolitinib). This approval is for the treatment of MET-amplified advanced gastric or gastroesophageal junction adenocarcinoma in patients w", "url": "https://grafa.com/en/news/united-states/hutchmed-orpathys-nmpa-approval-gastric-cancer", "source_name": "grafa.com", "published_at": "2026-07-02T12:40:41", "published_display": "02 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AIM movers: Hutchmed granted new drug application in China and ex-dividends", "summary": "Hutchmed (China) Ltd saw its share price jump after receiving conditional approval for its new drug ORPATHYS in China. Other companies like James Cropper, Zephyr Energy, James Latham, Sintana Energy, and Huddled Group also experienced share price increases due to positive develop", "url": "https://ukinvestormagazine.co.uk/aim-movers-hutchmed-granted-new-drug-application-in-china-and-ex-dividends/", "source_name": "UK Investor Magazine", "published_at": "2026-07-02T10:40:39", "published_display": "02 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NMPA clears HUTCHMED (HCM) drug ORPATHYS for MET-amplified gastric cancer", "summary": "HUTCHMED (HCM) has received conditional approval from China's National Medical Products Administration (NMPA) for its drug ORPATHYS (savolitinib) to treat locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with MET amplification, after at least two", "url": "https://www.stocktitan.net/sec-filings/HCM/6-k-hutchmed-china-ltd-current-report-foreign-issuer-03280d44d1ba.html", "source_name": "Stock Titan", "published_at": "2026-07-02T09:40:39", "published_display": "02 Jul 2026 09:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REG - Hutchmed China Ltd - HUTCHMED Announces NMPA Approval for ORPATHYS", "summary": "HUTCHMED (China) Limited announced that the China National Medical Products Administration (NMPA) has granted conditional approval for ORPATHYS\u00ae (savolitinib) to treat locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with MET ampl", "url": "https://www.tradingview.com/news/reuters.com,2026-07-02:newsml_RSB7781Ka:0-reg-hutchmed-china-ltd-hutchmed-announces-nmpa-approval-for-orpathys/", "source_name": "TradingView", "published_at": "2026-07-02T08:40:39", "published_display": "02 Jul 2026 08:40", "sentiment": "positive", "sentiment_pct": 93, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUTCHMED receives China approval for ORPATHYS in gastric cancer By Investing.com", "summary": "HUTCHMED announced that China's National Medical Products Administration has granted conditional approval for ORPATHYS (savolitinib) to treat advanced gastric cancer or gastroesophageal junction adenocarcinoma with MET amplification. This marks the first selective MET inhibitor a", "url": "https://ca.investing.com/news/stock-market-news/hutchmed-receives-china-approval-for-orpathys-in-gastric-cancer-93CH-4717673", "source_name": "Investing.com Canada", "published_at": "2026-07-02T08:40:39", "published_display": "02 Jul 2026 08:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "China approves HUTCHMED\u2019s ORPATHYS for MET-driven gastric cancer", "summary": "HUTCHMED (HCM) has received conditional NMPA approval in China for ORPATHYS (savolitinib) to treat locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with MET amplification. This approval marks the third indication for ORPATHYS in China and ", "url": "https://www.stocktitan.net/news/HCM/hutchmed-announces-nmpa-approval-for-orpathys-for-the-treatment-of-jcjoi1jarp14.html", "source_name": "Stock Titan", "published_at": "2026-07-02T08:40:39", "published_display": "02 Jul 2026 08:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUTCHMED to Announce 2026 Half-Year Financial Results", "summary": "HUTCHMED (China) Limited will announce its interim results for the first half of 2026 on Thursday, July 30, 2026. The company will host two webcast presentations for analysts and investors, one in English and one in Chinese (Putonghua), following the results announcement. These w", "url": "https://finance.yahoo.com/healthcare/articles/hutchmed-announce-2026-half-financial-083000053.html", "source_name": "Market source", "published_at": "2026-07-01T02:10:13", "published_display": "01 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUTCHMED to announce 2026 interim results on July 30", "summary": "HUTCHMED (China) Limited will release its interim financial results for the first half of 2026 on July 30, 2026. The company, focused on biopharmaceutical development for cancer and immunological diseases, will host two webcasts\u2014one in English and one in Chinese\u2014to discuss the re", "url": "https://scanx.trade/stock-market-news/companies/hutchmed-to-announce-2026-interim-results-on-july-30/44354258", "source_name": "scanx.trade", "published_at": "2026-06-30T11:40:54", "published_display": "30 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUTCHMED (NASDAQ: HCM) schedules 2026 half-year results and investor webcasts", "summary": "HUTCHMED (NASDAQ: HCM) has announced it will release its interim results for the first half of 2026 on Thursday, July 30, 2026. Management will host two webcasts for investors and analysts: an English webcast on July 30 and a Putonghua webcast on July 31. The company is a commerc", "url": "https://www.stocktitan.net/sec-filings/HCM/6-k-hutchmed-china-ltd-current-report-foreign-issuer-d3a5fb04297a.html", "source_name": "Stock Titan", "published_at": "2026-06-30T09:40:21", "published_display": "30 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUTCHMED to post half-year results July 30, with analyst webcasts", "summary": "HUTCHMED (Nasdaq/AIM: HCM; HKEX:13) announced it will release its 2026 half-year financial results on Thursday, July 30, 2026, at 7:00 am EDT. The company will host English and Chinese webcasts with Q&A sessions for analysts and investors, accessible live and via replay on its we", "url": "https://www.stocktitan.net/news/HCM/hutchmed-to-announce-2026-half-year-financial-7z0e5vutd92w.html", "source_name": "Stock Titan", "published_at": "2026-06-30T08:40:21", "published_display": "30 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REG - Hutchmed China Ltd - HUTCHMED to Announce 2026 Half-Year Results", "summary": "HUTCHMED (China) Limited will announce its interim financial results for the six months ended June 30, 2026, on Thursday, July 30, 2026. The company will host two webcast presentations for analysts and investors to discuss these results, with an English webcast on July 30 and a C", "url": "https://www.tradingview.com/news/reuters.com,2026-06-30:newsml_RSd2351Ka:0-reg-hutchmed-china-ltd-hutchmed-to-announce-2026-half-year-results/", "source_name": "TradingView", "published_at": "2026-06-30T08:40:20", "published_display": "30 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUTCHMED (HCM) details 2015 and 2026 share option blocklisting return", "summary": "HUTCHMED (China) Limited has filed a blocklisting six-monthly return for its 2015 and 2026 Share Option Schemes, covering the period from December 29, 2025, to June 28, 2026. The report details the issuance of 7,500 ordinary shares under the 2015 scheme, with 45,768,368 shares re", "url": "https://www.stocktitan.net/sec-filings/HCM/6-k-hutchmed-china-ltd-current-report-foreign-issuer-a51ed28dfa4e.html", "source_name": "Stock Titan", "published_at": "2026-06-29T10:39:27", "published_display": "29 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REG - Hutchmed China Ltd - Announcement on blocklisting six monthly return", "summary": "HUTCHMED (China) Limited has published its blocklisting six-monthly return for the period from December 29, 2025, to June 28, 2026. The report details the activity for two share option schemes, including the number of shares balance, increases, and securities issued during the pe", "url": "https://www.tradingview.com/news/reuters.com,2026-06-29:newsml_RSc0272Ka:0-reg-hutchmed-china-ltd-announcement-on-blocklisting-six-monthly-return/", "source_name": "TradingView", "published_at": "2026-06-29T08:39:27", "published_display": "29 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pivotal Phase II Results Advance HUTCHMED\u2019s Fanregratinib Towards China Approval In ICC", "summary": "HUTCHMED's fanregratinib has shown pivotal Phase II results, moving it closer to approval in China for intrahepatic cholangiocarcinoma (ICC). The article highlights the company's progress and mentions related news concerning competitors and other approvals in the field of cholang", "url": "https://insights.citeline.com/scrip/r-and-d/clinical-trials/pivotal-phase-ii-results-advance-hutchmeds-fanregratinib-towards-china-approval-in-icc-MSXLOHEOINE5XLW6DVRRCE5J5I/", "source_name": "Citeline News & Insights", "published_at": "2026-06-26T09:46:45", "published_display": "26 Jun 2026 09:46", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hutchmed Says Phase 2 Trial for Investigational Cancer Drug Meets Primary Endpoint", "summary": "Hutchmed announced that its investigational cancer drug, sovleplenib, met its primary endpoint in a Phase 2 trial. The study focused on adult patients with primary immune thrombocytopenia (ITP) who had previously failed at least one prior therapy. This positive outcome marks a si", "url": "https://www.moomoo.com/news/post/72026554/hutchmed-says-phase-2-trial-for-investigational-cancer-drug-meets?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-25T22:39:56", "published_display": "25 Jun 2026 22:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUTCHMED quarterly timing, shares steady on Nasdaq", "summary": "HUTCHMED (China) Ltd, an oncology-focused biotech company, is preparing to release its interim 2026 financial results in late August. While analysts hold mixed views on the stock, it trades steadily on Nasdaq, with its valuation sensitive to trial news and regulatory decisions. T", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/hutchmed-quarterly-timing-shares-steady-on-nasdaq/69627758", "source_name": "Ad-hoc-news.de", "published_at": "2026-06-25T20:11:50", "published_display": "25 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUTCHMED reports 42.5% fanregratinib response rate", "summary": "HUTCHMED announced positive Phase II data for its drug fanregratinib in patients with advanced intrahepatic cholangiocarcinoma, showing a 42.5% objective response rate in a single-arm trial conducted in China. The data supports a New Drug Application that has received priority re", "url": "https://grafa.com/en/news/united-states/hutchmed-fanregratinib-phase-ii-42-response-rate", "source_name": "grafa.com", "published_at": "2026-06-25T15:18:00", "published_display": "25 Jun 2026 15:18", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026", "summary": "HUTCHMED has released pivotal Phase II data for its drug fanregratinib (HMPL-453) in patients with intrahepatic cholangiocarcinoma (ICC) harboring FGFR2-fusions/rearrangements, which will be presented at the ESMO Gastrointestinal Cancers Congress 2026. The registration-enabling s", "url": "https://www.manilatimes.net/2026/06/25/tmt-newswire/globenewswire/hutchmed-highlights-pivotal-phase-ii-data-for-fanregratinib-in-intrahepatic-cholangiocarcinoma-presented-at-esmo-gastrointestinalcancers-congress-2026/2372436", "source_name": "The Manila Times", "published_at": "2026-06-25T12:40:21", "published_display": "25 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hutchmed China reports positive phase two fanregratinib study data", "summary": "Hutchmed China Ltd has reported positive phase two data for its drug fanregratinib, used to treat intrahepatic cholangiocarcinoma (ICC) in patients with fibroblast growth factor receptor two fusion/rearrangement. The study, conducted across 53 sites in China, met its primary endp", "url": "https://www.lse.co.uk/news/hutchmed-china-reports-positive-phase-two-fanregratinib-study-data-1yf3o07srvxfmvp.html", "source_name": "London South East", "published_at": "2026-06-25T11:25:00", "published_display": "25 Jun 2026 11:25", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pivotal fanregratinib ICC data and China NDA review for HUTCHMED (NASDAQ: HCM)", "summary": "HUTCHMED (NASDAQ: HCM) has reported pivotal Phase II data for its FGFR inhibitor fanregratinib in patients with advanced intrahepatic cholangiocarcinoma (ICC) harboring FGFR2 fusions or rearrangements. The study met its primary endpoint with an objective response rate of 42.5% an", "url": "https://www.stocktitan.net/sec-filings/HCM/6-k-hutchmed-china-ltd-current-report-foreign-issuer-bb54ad3c6970.html", "source_name": "Stock Titan", "published_at": "2026-06-25T10:11:49", "published_display": "25 Jun 2026 10:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RCS - Hutchmed China Ltd - HUTCHMED Highlights Phase II Data at ESMO", "summary": "HUTCHMED announced positive pivotal Phase II data for fanregratinib in intrahepatic cholangiocarcinoma (ICC) patients with FGFR2-fusions/rearrangements, to be presented at the ESMO Gastrointestinal Cancers Congress 2026. The study demonstrated a 42.5% objective response rate and ", "url": "https://www.tradingview.com/news/reuters.com,2026-06-25:newsml_RSY6204Ja:0-rcs-hutchmed-china-ltd-hutchmed-highlights-phase-ii-data-at-esmo/", "source_name": "TradingView", "published_at": "2026-06-25T06:11:49", "published_display": "25 Jun 2026 06:11", "sentiment": "positive", "sentiment_pct": 87, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUTCHMED analyst targets stay high, shares trade well below consensus", "summary": "HUTCHMED (HCM) shares are trading significantly below analyst price targets, with the ADR closing around $10 while the consensus target remains above $20. The average analyst price target for HUTCHMED ADR is $21.07, representing over 100% upside from its current price, and the co", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/hutchmed-analyst-targets-stay-high-shares-trade-well-below-consensus/69612949", "source_name": "AD HOC NEWS", "published_at": "2026-06-23T18:40:23", "published_display": "23 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 69, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/hutchmed-highlights-sovleplenib-eslim-02-000000864.html", "source_name": "GlobeNewswire", "published_at": "2026-06-12T00:00:00+00:00", "published_display": "12 Jun 2026 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why HUTCHMED (China) Limited (HCM) Is Gaining Attention After China Biotech Re-Rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQRFFZbzFnWWV2S09idXNwVVFqZ2c1Sl9sellQNHZGb2pEMVZlYnZDLS1ZQXlaTGNwRlpzN00wUm5EUUhjVzdrTC1yVGwtWVlucUZZeXNpdFNSYndrUHoxY0xESEkxZS1TMXpfVWcteTFDX3JBbnB4S2MtSnBGLWFhaUt3M3hpMk1YbjJjRG1iWW1OV2JGcVBEQ3ptNDB6NXAx?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hutchmed stock hits 52-week low at 11.7 USD", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQaFJHUWxSLXVjY1dlbjRXdjJ6Mi1WZzBFdHZ3aWZXV2J4TEQ2ZFA2ejdoRi03bjlkdXhzVC0wMURtWmNJTHBrMXNjZHhqZG1TU29HYkllYmcydGlsYmprWUk1cFJXS3dYQ3hDRkQ0dDJ6UDYtaW5kUkNCaE5OdGhqdldKVjJ1MUdZdk0zTFZrNlRzSE1yd0ZCT0oxOUMzWjA?oc=5", "source_name": "Investing.com", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT\u00ae (Sintilimab Injection) in Combination with ELUNATE\u00ae (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/innovent-hutchmed-jointly-announce-nmpa-100000286.html", "source_name": "PR Newswire", "published_at": "2026-05-21T10:00:00+00:00", "published_display": "21 May 2026 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE\u00ae (Fruquintinib) in Combination with TYVYT\u00ae (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/hutchmed-innovent-jointly-announce-nmpa-100000086.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T10:00:00+00:00", "published_display": "21 May 2026 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/hutchmed-announces-nda-acceptance-china-100000447.html", "source_name": "GlobeNewswire", "published_at": "2026-04-29T10:00:00+00:00", "published_display": "29 Apr 2026 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 74, "total_relevant": 35, "sentiment_summary": {"positive": 19, "negative": 0, "neutral": 16, "score": 66, "total": 35, "label": "Constructive news tone", "tone": "positive"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 73, "events": [{"event": "general", "label": "Market update", "weight": 7.15, "count": 13}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 6.6, "count": 12}, {"event": "earnings", "label": "Earnings", "weight": 3.85, "count": 7}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 19, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 11.07, "latest_week": "2026-07-10", "one_week_move": -3.2, "four_week_move": 1.0, "twelve_week_move": -29.7, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.065459, "market_dynamics_buy_signal": false, "relative_strength": -34.752943, "fair_value_gap": -30.0, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 52.0848, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-3.2% over one week, +1.0% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Positive news being faded", "tone": "negative", "classification": "positive_rejected", "summary": "Constructive headlines are not being rewarded by price, which raises a rejection flag.", "confidence": 75, "badges": ["Sentiment-trend disagreement", "Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": ["Positive news is arriving while the Sharemaestro trend signal is inactive."], "event_label": "Market update", "sentiment_word": "constructive"}, "charts": {"sources": [{"label": "Stock Titan", "count": 6}, {"label": "TradingView", "count": 4}, {"label": "Market source", "count": 3}, {"label": "GlobeNewswire", "count": 3}, {"label": "Moomoo", "count": 2}, {"label": "Investing.com Canada", "count": 2}, {"label": "London South East", "count": 2}, {"label": "grafa.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 35}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 13}, {"label": "Regulatory and legal", "count": 12}, {"label": "Earnings", "count": 7}, {"label": "Analyst action", "count": 2}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "66/100", "tone": "positive", "text": "Constructive news tone"}, {"label": "Market reaction", "value": "Positive news being faded", "tone": "negative", "text": "Constructive headlines are not being rewarded by price, which raises a rejection flag."}, {"label": "Primary event", "value": "Market update", "tone": "positive", "text": "73/100 classification confidence."}, {"label": "Company focus", "value": "35", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-3.2% over one week, +1.0% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "HUTCHMED (China) Ltd (HCM) Shares Surge 3.0% -- What GF Score of 79 Tells Investors"}], "updated_at": "2026-07-16T12:56:52.385087+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}